Renata Ferrarotto - Next Frontiers to Cure Cancer 2021

Renata Ferrarotto

University of Texas M.D. Anderson Cancer Center

Dr. Ferrarotto is an Associate Professor in the Department of Thoracic Head and Neck Medical Oncology, and serves as Director of Clinical Research in Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.  She currently has 7 investigator-initiated trials approved, 6 with immunotherapy agents. She has identified NOTCH1 as the mostly mutated gene in Adenoid Cystic Carcinoma (ACC) and as a targetable oncogenic driver in this type of cancer (Ferrarotto et al, J Clin Oncol, 2017). She initiated and led the first biomarker-specific study in ACC investigating AL101 in NOTCH-activated metastatic ACC (NCT03691207). Her group has further completed the first comprehensive proteogenomic analysis of a large cohort of 54 ACC with annotated clinicopathologic data (Ferrarotto R, et al, Clin Cancer Res, 2021), which could help stratify patients and identify potential biomarkers for co-targeting with NOTCH inhibitors. Recently she was awarded a DOD grant entitled “Characterization and targeting NOTCH activated ACC”.